Eris Lifesciences faces HALMED non compliance observations at Swiss Parenterals plants in Ahmedabad, plans GMP remediation with limited business impact expected. Shares of Eris Lifesciences Ltd ended marginally lower on Monday, April 20, by 0.91% at 1,432.40 on the NSE.
Eris Lifesciences says issues found at Swiss Parenterals units; impact likely minimal
Source: Cnbctv18
Read Full Story →
